General Information of Drug (ID: DMWCQP4)

Drug Name
Interferon Alfa-2b
Synonyms Intron A; Viraferon
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Sequence
CDLPQTHSLGSRRTLMLLAQMRRISLFSCLKDRHDFGFPQEEFGNQFQKAETIPVLHEMI
QQIFNLFSTKDSSAAWDETLLDKFYTELYQQLNDLEACVIQGVGVTETPLMNEDSILAVR
KYFQRITLYLKEKKYSPCAWEVVRAEIMRSFSLSTNLQESLRSKE
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski):
1
Molecular Weight 746.5
Logarithm of the Partition Coefficient Not Available
Rotatable Bond Count 7
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 6
ADMET Property
Absorption
The absorption of drug is greater than 80% from intramuscular or subcutaneous injections []
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [2]
Chemical Identifiers
Formula
C16H17Cl3I2N3NaO5S
IUPAC Name
sodium;diiodomethanesulfonate;N-propyl-N-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide
Canonical SMILES
CCCN(CCOC1=C(C=C(C=C1Cl)Cl)Cl)C(=O)N2C=CN=C2.C(S(=O)(=O)[O-])(I)I.[Na+]
InChI
InChI=1S/C15H16Cl3N3O2.CH2I2O3S.Na/c1-2-4-20(15(22)21-5-3-19-10-21)6-7-23-14-12(17)8-11(16)9-13(14)18;2-1(3)7(4,5)6;/h3,5,8-10H,2,4,6-7H2,1H3;1H,(H,4,5,6);/q;;+1/p-1
InChIKey
MIXCUJKCXRNYFM-UHFFFAOYSA-M
Cross-matching ID
PubChem CID
71306834
CAS Number
98530-12-2
DrugBank ID
DB00105
TTD ID
D0P0WV
ACDINA ID
D01166
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interferon-alpha 2 (IFNA2) TTSIUJ9 IFNA2_HUMAN Modulator [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
2'-5'-oligoadenylate synthase 1 (OAS1) OT8ZLOCY OAS1_HUMAN Gene/Protein Processing [4]
Interferon-induced, double-stranded RNA-activated protein kinase (EIF2AK2) OT8DXMS3 E2AK2_HUMAN Gene/Protein Processing [4]
Non-receptor tyrosine-protein kinase TYK2 OTHEOTA8 TYK2_HUMAN Gene/Protein Processing [4]
Signal transducer and activator of transcription 1-alpha/beta (STAT1) OTLMBUZ6 STAT1_HUMAN Gene/Protein Processing [4]
Signal transducer and activator of transcription 2 (STAT2) OTO9G2RZ STAT2_HUMAN Post-Translational Modifications [4]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Post-Translational Modifications [4]
Tyrosine-protein kinase JAK1 (JAK1) OT0X3D17 JAK1_HUMAN Gene/Protein Processing [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Melanoma
ICD Disease Classification 2C30
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interferon-alpha 2 (IFNA2) DTT IFNA2 9.31E-04 0.35 2.05
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Interferon Alfa-2b (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [5]
Thioguanine DM7NKEV Moderate Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and Thioguanine. Acute myeloid leukaemia [2A60] [6]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [7]
Aminophylline DML2NIB Moderate Decreased metabolism of Interferon alfa-2B caused by Aminophylline mediated inhibition of CYP450 enzyme. Asthma [CA23] [5]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Interferon alfa-2B and Roflumilast. Asthma [CA23] [8]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [9]
Oxtriphylline DMLHSE3 Moderate Decreased metabolism of Interferon alfa-2B caused by Oxtriphylline mediated inhibition of CYP450 enzyme. Cough [MD12] [5]
PMID28870136-Compound-48 DMPIM9L Moderate Decreased metabolism of Interferon alfa-2B caused by PMID28870136-Compound-48 mediated inhibition of CYP450 enzyme. Discovery agent [N.A.] [5]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and Cannabidiol. Epileptic encephalopathy [8A62] [8]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Interferon alfa-2B and Brentuximab vedotin. Hodgkin lymphoma [2B30] [10]
Efavirenz DMC0GSJ Moderate Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [11]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Interferon alfa-2B and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [12]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and Mipomersen. Hyper-lipoproteinaemia [5C80] [13]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Interferon alfa-2B and Teriflunomide. Hyper-lipoproteinaemia [5C80] [14]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and BMS-201038. Hyper-lipoproteinaemia [5C80] [15]
Ramelteon DM7IW9J Moderate Decreased metabolism of Interferon alfa-2B caused by Ramelteon mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [16]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Interferon alfa-2B and Polyethylene glycol. Irritable bowel syndrome [DD91] [17]
Methotrexate DM2TEOL Moderate Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and Methotrexate. Leukaemia [2A60-2B33] [8]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Interferon alfa-2B and Denosumab. Low bone mass disorder [FB83] [18]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [19]
Cladribine DM3JDRP Major Additive myelosuppressive effects by the combination of Interferon alfa-2B and Cladribine. Mature B-cell leukaemia [2A82] [8]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and Idelalisib. Mature B-cell leukaemia [2A82] [20]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and Clofarabine. Mature B-cell lymphoma [2A85] [21]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Interferon alfa-2B and Thalidomide. Multiple myeloma [2A83] [12]
Bortezomib DMNO38U Moderate Increased risk of peripheral neuropathy by the combination of Interferon alfa-2B and Bortezomib. Multiple myeloma [2A83] [12]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Interferon alfa-2B and Tecfidera. Multiple sclerosis [8A40] [22]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Interferon alfa-2B and Siponimod. Multiple sclerosis [8A40] [5]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Interferon alfa-2B and Fingolimod. Multiple sclerosis [8A40] [23]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Interferon alfa-2B and Ocrelizumab. Multiple sclerosis [8A40] [24]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Interferon alfa-2B and Ozanimod. Multiple sclerosis [8A40] [8]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Interferon alfa-2B and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [25]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Interferon alfa-2B and Bupropion. Nicotine use disorder [6C4A] [26]
Tramadol DMRQD04 Major Increased risk of lowers seizure threshold by the combination of Interferon alfa-2B and Tramadol. Pain [MG30-MG3Z] [27]
Rasagiline DM3WKQ4 Moderate Decreased metabolism of Interferon alfa-2B caused by Rasagiline mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [5]
Ropinirole DMA6S1D Moderate Decreased metabolism of Interferon alfa-2B caused by Ropinirole mediated inhibition of CYP450 enzyme. Parkinsonism [8A00] [28]
Lindane DMB8CNL Moderate Increased risk of lowers seizure threshold by the combination of Interferon alfa-2B and Lindane. Pediculosis [1G00] [29]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [8]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Interferon alfa-2B and Naltrexone. Substance abuse [6C40] [30]
Tizanidine DMR2IQ4 Major Decreased metabolism of Interferon alfa-2B caused by Tizanidine mediated inhibition of CYP450 enzyme. Tonus and reflex abnormality [MB47] [31]
Azathioprine DMMZSXQ Moderate Additive immunosuppressive effects by the combination of Interferon alfa-2B and Azathioprine. Transplant rejection [NE84] [5]
Ganciclovir DM1MBYQ Moderate Additive myelosuppressive effects by the combination of Interferon alfa-2B and Ganciclovir. Virus infection [1A24-1D9Z] [5]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Interferon alfa-2B and Valganciclovir. Virus infection [1A24-1D9Z] [5]
⏷ Show the Full List of 42 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Metacresol E00016 342 Antimicrobial preservative
Disodium hydrogenorthophosphate E00283 24203 Buffering agent; Complexing agent
Edetate disodium E00186 8759 Complexing agent
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Saccharose E00091 5988 Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium dihydrogenorthophosphate E00559 23672064 Buffering agent; Complexing agent
Water E00035 962 Solvent
⏷ Show the Full List of 8 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Interferon Alfa-2B 10miu/vial powder For Injection 10miu/vial Powder For Injection Intramuscular; Subcutaneous; Intralesional; Intravenous
Interferon Alfa-2B 50ug/0.5ml solution 50ug/0.5ml Solution Subcutaneous
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 6-Hydroxy-3-O-methyl-kaempferol 6-O-glucopyranoside potentiates the anti-proliferative effect of interferon / by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells. Toxicol Appl Pharmacol. 2017 Dec 1;336:31-39. doi: 10.1016/j.taap.2017.10.004. Epub 2017 Oct 12.
5 Cerner Multum, Inc. "Australian Product Information.".
6 Product Information. Aubagio (teriflunomide). Genzyme Corporation, Cambridge, MA.
7 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
8 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
9 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
10 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
11 Elsharkawy AM, Schwab U, McCarron B, et al. "Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser." J Clin Virol 58 (2013): 331-3. [PMID: 23763943]
12 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
13 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
14 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
15 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
16 Product Information. Rozerem (ramelteon). Takeda Pharmaceuticals America, Lincolnshire, IL.
17 Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
18 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
19 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
20 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
21 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
22 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
23 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
24 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
25 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
26 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
27 Product Information. Ultram (tramadol). McNeil Pharmaceutical, Raritan, NJ.
28 Product Information. Noroxin (norfloxacin). Merck & Co, Inc, West Point, PA.
29 Matsuoka LY "Convulsions following application of gamma benzene hexachloride." J Am Acad Dermatol 5 (1981): 98-9. [PMID: 6168673]
30 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
31 Granfors MT, Backman JT, Laitila J, Neuvonen PJ "Tizanidine is mainly metabolized by cytochrome P450 1A2 in vitro." Br J Clin Pharmacol 57 (2004): 349-53. [PMID: 14998432]